1.92
+0.32(+20.00%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.78 |
| Day High | 4.07 |
| Day Low | 1.7 |
| 52-Week High | 5.99 |
| 52-Week Low | 0.95 |
| Volume | 62.55M |
| Average Volume | 117,741 |
| Market Cap | 21.72M |
| PE | -1.45 |
| EPS | -1.32 |
| Moving Average 50 Days | 1.41 |
| Moving Average 200 Days | 2.22 |
| Change | 0.32 |
If you invested $1000 in Marker Therapeutics, Inc. (MRKR) 10 years ago, it would be worth $24.11 as of July 17, 2025 at a share price of $2.17. Whereas If you bought $1000 worth of Marker Therapeutics, Inc. (MRKR) shares 5 years ago, it would be worth $118.58 as of July 17, 2025 at a share price of $2.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
GlobeNewswire Inc.
Jun 17, 2025 12:00 PM GMT
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data readout from Phase
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology co